source
- Angitia halts Phase 3 trial of AGA111 for degenerative disc diseaseAngitia Biopharmaceuticals announced that it has ended the Phase 3 study of its investigational therapy AGA111 in patients with degenerative disc disease who had undergone lumbar interbody fusion.…
- Merck ends Phase 2 trial of Alzheimer’s drug MK-1167 from partner NeuphoriaMerck announced it has terminated a mid-stage Phase 2 study of an experimental Alzheimer’s therapy. The drug, called MK-1167, is an oral candidate that was being developed in collaboration with bi…